As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:
6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -5.68 -5.68 |
39%
39%
|
EBIT (Operating Income) EBIT | -5.68 -5.68 |
39%
39%
|
Net Profit | -5.57 -5.57 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.
Head office | United States |
CEO | David Arthur |
Employees | 2 |
Founded | 2014 |
Website | salariuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.